Stryker Corporation is a premier medical technology company specializing in orthopedic implants, surgical equipment, and neurotechnology " product lines directly aligned with aging population demographics. As joint replacements, spinal surgeries, and hospital procedures increase with an older global population, Stryker stands to benefit from durable, secular tailwinds.

Financially, Stryker demonstrates consistent revenue growth, strong margins, and a track record of accretive acquisitions (notably Wright Medical and MAKO Surgical). The company's robotic-assisted surgery platform (Mako) provides a competitive moat and positions it well against peers like Zimmer Biomet and Medtronic. Trading near $366, the stock sits roughly 10% below its 52-week high, potentially offering a reasonable entry point, though its premium valuation (typically 25-30x forward earnings) demands continued execution.

Bull case: Irreversible demographic trends, innovation leadership in robotics, and pricing power. Bear case: Elevated valuation, potential hospital spending slowdowns, and integration risks from acquisitions. Stryker remains one of the strongest pure-play investments on global aging, combining quality management with a defensible market position.